Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

GT Biopharma Inc (GTBP)

GT Biopharma Inc (GTBP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 379,881
  • Shares Outstanding, K 21,128
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,300 K
  • 60-Month Beta 0.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 21.27
Trade GTBP with:

Options Overview

Details
  • Implied Volatility 0.00%
  • Historical Volatility 82.03%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.28
  • Number of Estimates 3
  • High Estimate -0.20
  • Low Estimate -0.32
  • Prior Year -1.36
  • Growth Rate Est. (year over year) +79.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.58 +42.93%
on 05/19/21
19.73 -8.88%
on 06/14/21
+4.83 (+36.73%)
since 05/18/21
3-Month
6.09 +195.24%
on 03/25/21
19.73 -8.88%
on 06/14/21
+11.85 (+193.31%)
since 03/18/21
52-Week
2.04 +780.64%
on 07/08/20
19.73 -8.88%
on 06/14/21
+14.58 (+428.82%)
since 06/18/20

Most Recent Stories

More News
GT Biopharma to Present at Raymond James Human Health Innovation Conference

BEVERLY HILLS, Calif., /PRNewswire/ --GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based...

GTBP : 17.98 (-0.06%)
GT Biopharma to be Added to the Russell 2000® Index

/PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary...

GTBP : 17.98 (-0.06%)
Dow Jumps Over 140 Points as Jobless Claims Continue to Decline

Dow Jumps Over 140 Points as Jobless Claims Continue to Decline

LOGI : 123.78 (-1.86%)
EVER : 33.97 (+0.74%)
SNX : 117.61 (-1.70%)
AAPL : 130.46 (-1.01%)
NTAP : 78.16 (-4.06%)
HUN : 24.81 (-4.02%)
ABNB : 152.52 (+1.21%)
BYD : 58.68 (-2.00%)
NUE : 93.02 (-2.34%)
UCO : 73.55 (+1.07%)
AMC : 59.26 (-2.42%)
GME : 213.82 (-4.37%)
CRM : 242.78 (-0.68%)
NVDA : 745.55 (-0.10%)
RAIL : 5.36 (-1.47%)
SAVA : 79.65 (+1.34%)
GTBP : 17.98 (-0.06%)
GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET

, /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage biopharmaceutical company focused on the development and commercialization of disruptive, target-directed Natural Killer (NK) cell...

GTBP : 17.98 (-0.06%)
GT Biopharma Reports First Quarter 2021 Results

, /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary...

GTBP : 17.98 (-0.06%)
OXIS International Inc. (GTBP) Gains As Market Dips: What You Should Know

OXIS International Inc. (GTBP) closed the most recent trading day at $12.51, moving +1.54% from the previous trading session.

GTBP : 17.98 (-0.06%)
GT Biopharma (GTBP) to Report Q1 Earnings: What to Expect?

GT Biopharma (GTBP) is expected to provide updates on its pipeline development when it reports first-quarter 2021 result.

FBIO : 3.50 (-2.78%)
GTBP : 17.98 (-0.06%)
BYSI : 11.68 (+3.18%)
AVRO : 9.34 (-3.21%)
GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates

, /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE™)...

GTBP : 17.98 (-0.06%)
Dow Drops Over 1% on Market's Second Straight Day of Losses

Dow Drops Over 1% on Market's Second Straight Day of Losses

HIMX : 14.00 (-2.23%)
EXTR : 10.41 (-6.13%)
IMMR : 8.26 (-7.40%)
ACCO : 8.30 (-3.38%)
BOOT : 74.89 (-1.03%)
AVT : 38.85 (-4.38%)
MGNI : 29.49 (-6.77%)
TTD : 60.88 (-2.03%)
LUV : 55.19 (-0.68%)
TMUS : 144.70 (-1.19%)
CHGG : 79.99 (+1.87%)
HTHT : 54.65 (+2.28%)
NLS : 15.67 (-2.37%)
GTBP : 17.98 (-0.06%)
CCRN : 17.81 (-3.73%)
AAPL : 130.46 (-1.01%)
TSLA : 623.31 (+1.09%)
AMZN : 3,486.90 (-0.07%)
NFLX : 500.77 (+0.49%)
Dow Reaches New Record While Tech Remains Under Pressure

Dow Reaches New Record While Tech Remains Under Pressure

ECHO : 30.59 (-1.70%)
SLCA : 11.10 (-0.98%)
DDS : 154.02 (-2.93%)
PRFT : 79.76 (+0.73%)
AA : 32.08 (-4.47%)
DBC : 18.62 (+1.03%)
DVN : 26.75 (-3.04%)
JO : 42.56 (+0.47%)
MRC : 9.68 (-0.62%)
GTBP : 17.98 (-0.06%)
FB : 329.66 (-2.04%)
AMZN : 3,486.90 (-0.07%)
NFLX : 500.77 (+0.49%)
AAPL : 130.46 (-1.01%)
SQ : 237.05 (+0.39%)
ROKU : 368.43 (+4.58%)
MRNA : 199.19 (-1.62%)
GRPN : 43.05 (-1.76%)
PENN : 73.78 (-3.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs. GT Biopharma Inc., formerly known as OXIS International Inc., is based in Tampa, Florida.

See More

Key Turning Points

3rd Resistance Point 18.95
2nd Resistance Point 18.50
1st Resistance Point 18.24
Last Price 17.98
1st Support Level 17.53
2nd Support Level 17.08
3rd Support Level 16.82

See More

52-Week High 19.73
Last Price 17.98
Fibonacci 61.8% 12.97
Fibonacci 50% 10.89
Fibonacci 38.2% 8.80
52-Week Low 2.04

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar